GAS6 and chronic myelogenous leukemia, BCR-ABL1 positive: The GAS6/AXL complex has been shown to stabilize β-catenin in human CML CD4+ cells, presenting a potential target for eliminating CML LSCs.107 Therefore, targeting AXL or its signaling pathways may enhance clinical response to anticancer therapies by reducing stemness, recurrence and metastasis.